Combs Andrew 4
4 · Prelude Therapeutics Inc · Filed Sep 29, 2020
Insider Transaction Report
Form 4
Combs Andrew
Chief Chemistry Officer
Transactions
- Purchase
Common Stock
2020-09-29$19.00/sh+1,000$19,000→ 260,380 total
Footnotes (1)
- [F1]Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.